Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity

References

• Peyrone M. Ueber die Einwirkung des Ammoniaks auf Platinchlorür. Justus Liebigs Annalen der Chemie. 1844;51(1):1–29.
   Google Scholar
• Alderden RA, Hall MD, Hambley TW. The discovery and development of cisplatin. J Chem Educ. 2006;83(5):728.
   Google Scholar
• Muggia FM, Bonetti A, Hoeschele JD, et al. Platinum antitumor complexes: 50 years since Barnett Rosenberg’s discovery. J Clin Oncol. 2015;33(35):4219–4226.
   Google Scholar
• Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698–699.
   Google Scholar
• Rosenberg B, Van Camp L, Grimley EB, et al. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J Biol Chem. 1967;242(6):1347–1352.
   Google Scholar
• Rosenberg B, Van Camp L, Trosko JE, et al. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222(5191):385–386.
   Google Scholar
• Rosenberg B, Renshaw E, Vancamp L, et al. Platinum-induced filamentous growth in Escherichia coli. J Bacteriol. 1967;93(2):716–721.
   Google Scholar
• Cleare MJ, Hoeschele JD. Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum (II) complexes. Bioinorg Chem. 1973;2(3):187–210.
   Google Scholar
• Cleare MJ, Hoeschele J. Antitumour platinum compounds. Platinum Metals Rev. 1973;17(1):2–13.
   Google Scholar
• Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer. 1977;39(4):1357–1361.
   Google Scholar
• Barnard C. Platinum anti-cancer agents. Platinum Met Rev. 1989;33(4):162–167.
   Google Scholar
• Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1998;34(10):1522–1534.
   Google Scholar
• Cubeddu LX, Hoffmann IS, Fuenmayor NT, et al. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990;322(12):810–816.
   Google Scholar
• Wheate NJ, Walker S, Craig GE, et al. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010;39(35):8113–8127.
   Google Scholar
• Johnson NP, Hoeschele JD, Rahn RO, et al. Mutagenicity, cytotoxicity, and DNA binding of platinum(II)-chloroammines in Chinese hamster ovary cells. Cancer Res. 1980;40(5):1463–1468.
   Google Scholar
• Fichtinger-Schepman AM, Van der Veer JL, Den Hartog JHJ, et al. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry. 1985;24(3):707–713.
   Google Scholar
• Fichtinger-Schepman AM, PH Lohman, F Berends, et al. Interactions of the antitumour drug cisplatin with DNA in vitro and in vivo. IARC Sci Publ. 1986;78:83–99.
   Google Scholar
• Eastman A, Barry MA. Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry. 1987;26(12):3303–3307.
   Google Scholar
• Takahara PM, Rosenzweig AC, Frederick CA, et al. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature. 1995;377(6550):649–652.
   Google Scholar
• Gately D, Howell S. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer. 1993;67(6):1171–1176.
   Google Scholar
• Ivanov AI, Christodoulou J, Parkinson JA, et al. Cisplatin binding sites on human albumin. J Biol Chem. 1998;273(24):14721–14730.
   Google Scholar
• Kratz F, Keppler B. Metal complexes in cancer chemotherapy. VCH. 1993;1:391–395.
   Google Scholar
• DeConti RC, Toftness BR, Lange RC, et al. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res. 1973;33(6):1310–1315.
   Google Scholar
• Borch RF, Pleasants ME. Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model. Proc Nat Acad Sci. 1979;76(12):6611–6614.
   Google Scholar
• Andrews PA, Wung WE, Howell SB. A high-performance liquid chromatographic assay with improved selectivity for cisplatin and active platinum (II) complexes in plasma ultrafiltrate. Anal Biochem. 1984;143(1):46–56.
   Google Scholar
• Barnham KJ, Djuran MI, Murdoch PDS, et al. Ring-opened adducts of the anticancer drug carboplatin with sulfur amino acids. Inorg Chem. 1996;35(4):1065–1072.
   Google Scholar
• Dolman RC, Deacon GB, Hambley TW. Studies of the binding of a series of platinum (IV) complexes to plasma proteins. J Inorg Biochem. 2002;88(3–4):260–267.
   Google Scholar
• Lempers EL, Reedijk J. Interactions of platinum amine compounds with sulfur-containing biomolecules and DNA fragments. In: Advances in inorganic chemistry. Amsterdam, The Netherlands: Elsevier; 1991. p. 175–217.
   Google Scholar
• Abada P, Howell SB. Regulation of cisplatin cytotoxicity by cu influx transporters. Met Based Drugs. 2010;2010:317581.
   Google Scholar
• Song IS, Savaraj N, Siddik ZH, et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther. 2004;3(12):1543–1549.
   Google Scholar
• Blair BG, Larson CA, Safaei R, et al. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. Clin Cancer Res. 2009;15(13):4312–4321.
   Google Scholar
• Bompiani KM, Tsai C-Y, Achatz FP, et al. Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. Metallomics. 2016;8(9):951–962.
   Google Scholar
• Yoshizawa K, Nozaki S, Kitahara H, et al. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines. Oncol Rep. 2007;18(4):987–991.
   Google Scholar
• Harrach S, Ciarimboli G. Role of transporters in the distribution of platinum-based drugs. Front Pharmacol. 2015;6:85.
   Google Scholar
• Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 2004;308(1):2–9.
   Google Scholar
• Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24(7):1227–1251.
   Google Scholar
• Bancroft DP, Lepre CA, Lippard SJ. Platinum-195 NMR kinetic and mechanistic studies of cis-and trans-diamminedichloroplatinum (II) binding to DNA. J Am Chem Soc. 1990;112(19):6860–6871.
   Google Scholar
• Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478(1–2):23–43.
   Google Scholar
• LeDoux SP, Wilson GL, Beecham EJ, et al. Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells. Carcinogenesis. 1992;13(11):1967–1973.
   Google Scholar
• Shu X, Xiong X, Song J, et al. Base-resolution analysis of cisplatin-DNA adducts at the genome scale. Angew Chem Int Ed Engl. 2016;55(46):14246–14249.
   Google Scholar
• Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res. 1988;48(16):4484–4488.
   Google Scholar
• Cepeda V, Fuertes M, Castilla J, et al. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007;7(1):3–18.
   Google Scholar
• Gonzalez VM, Fuertes MA, Alonso C, et al. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol. 2001;59(4):657–663.
   Google Scholar
• Xu Y, Ma H-B, Fang Y-L, et al. Cisplatin-induced necroptosis in TNFalpha dependent and independent pathways. Cell Signal. 2017;31:112–123.
   Google Scholar
• Yu W, Chen Y, Dubrulle J, et al. Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep. 2018;8(1):4306.
   Google Scholar
• Dixon SJ, Lemberg K, Lamprecht M, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072.
   Google Scholar
• Vandenabeele P, Galluzzi L, Vanden Berghe T, et al. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11(10):700–714.
   Google Scholar
• Rybak LP, Whitworth CA, Mukherjea D, et al. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 2007;226(1–2):157–167.
   Google Scholar
• Kros CJ, Steyger PS. Aminoglycoside- and cisplatin-induced ototoxicity: mechanisms and otoprotective strategies. Cold Spring Harb Perspect Med. 2019;9(11):a033548.
   Google Scholar
• Rybak LP, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Semin Hear. 2019;40(2):197–204.
   Google Scholar
• Santos N, Ferreira RS, Santos ACD. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Food Chem Toxicol. 2020;136:111079.
   Google Scholar
• Skinner R, Pearson A, English MW, et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer. 1998;77(10):1677–1682.
   Google Scholar
• Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23(34):8588–8596.
   Google Scholar
• Knight KR, Kraemer DF, Winter C, et al. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25(10):1190–1195.
   Google Scholar
• Coradini PP, Cigana L, Selistre SGA, et al. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29(6):355–360.
   Google Scholar
• Hayati F, Hossainzadeh M, Shayanpour S, et al. Prevention of cisplatin nephrotoxicity. J Nephropharmacol. 2016;5(1):57–60.
   Google Scholar
• Yu D, Gu J, Chen Y, et al. Current strategies to combat cisplatin-induced ototoxicity. Front Pharmacol. 2020;11(999):1–12.
   Google Scholar
• Sheth S, Mukherjea D, Rybak LP, et al. Mechanisms of cisplatin-induced ototoxicity and otoprotection. Front Cell Neurosci. 2017;11:338.
   Google Scholar
• Pierson MG, Gray BH. Superoxide dismutase activity in the cochlea. Hear Res. 1982;6(2):141–151.
   Google Scholar
• Usami S, Hjelle OP, Ottersen OP. Differential cellular distribution of glutathione–an endogenous antioxidant–in the guinea pig inner ear. Brain Res. 1996;743(1–2):337–340.
   Google Scholar
• Seidman MD, Quirk WS, Nuttall AL, et al. The protective effects of allopurinol and superoxide dismutase-polyethylene glycol on ischemic and reperfusion-induced cochlear damage. Otolaryngol Head Neck Surg. 1991;105(3):457–463.
   Google Scholar
• Clerici WJ, Yang L. Direct effects of intraperilymphatic reactive oxygen species generation on cochlear function. Hear Res. 1996;101(1–2):14–22.
   Google Scholar
• Kopke RD, Liu W, Gabaizadeh R, et al. Use of organotypic cultures of Corti’s organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol. 1997;18(5):559–571.
   Google Scholar
• Banfi B, B Malgrange, J Knisz, et al. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem. 2004;279(44):46065–46072.
   Google Scholar
• Lynch ED, Gu R, Pierce C, et al. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res. 2005;201(1–2):81–89.
   Google Scholar
• Church MW, Kaltenbach JA, Blakley BW, et al. The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res. 1995;86(1–2):195–203.
   Google Scholar
• Rybak LP, Ravi R, Somani SM. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol. 1995;26(2):293–300.
   Google Scholar
• Kruidering M, Van De Water B, De Heer E, et al. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther. 1997;280(2):638–649.
   Google Scholar
• Mukherjea D, Jajoo S, Kaur T, et al. Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat. Antioxid Redox Signal. 2010;13(5):589–598.
   Google Scholar
• Kim HJ, Lee JH, Kim SJ, et al. Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci. 2010;30(11):3933–3946.
   Google Scholar
• Lee JE, Nakagawa T, Kim TS, et al. Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment. Acta Otolaryngol. 2004;124(10):1131–1135.
   Google Scholar
• Jamesdaniel S, Coling D, Hinduja S, et al. Cisplatin-induced ototoxicity is mediated by nitroxidative modification of cochlear proteins characterized by nitration of Lmo4. J Biol Chem. 2012;287(22):18674–18686.
   Google Scholar
• Watanabe K, Inai S, Jinnouchi K, et al. Nuclear-factor kappa B (NF-kappa B)-inducible nitric oxide synthase (iNOS/NOS II) pathway damages the stria vascularis in cisplatin-treated mice. Anticancer Res. 2002;22(6C):4081–4085.
   Google Scholar
• Li G, Liu W, Frenz D. Cisplatin ototoxicity to the rat inner ear: a role for HMG1 and iNOS. Neurotoxicology. 2006;27(1):22–30.
   Google Scholar
• Watanabe K-I, Hess A, Michel O, et al. Nitric oxide synthase inhibitor reduces the apoptotic change in the cisplatin-treated cochlea of guinea pigs. Anticancer Drugs. 2000;11(9):731–735.
   Google Scholar
• Jamesdaniel S, Ding D, Kermany MH, et al. Proteomic analysis of the balance between survival and cell death responses in cisplatin-mediated ototoxicity. J Proteome Res. 2008;7(8):3516–3524.
   Google Scholar
• Paciello F, Rita Fetoni A, Mezzogori D, et al. The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity. Sci Rep. 2020;10(1):1063.
   Google Scholar
• Kim HJ, Oh GS, Shen A, et al. Augmentation of NAD(+) by NQO1 attenuates cisplatin-mediated hearing impairment. Cell Death Dis. 2014;5:e1292.
   Google Scholar
• Gerber DE, Beg MS, Fattah F, et al. Phase 1 study of ARQ 761, a beta-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. Br J Cancer. 2018;119(8):928–936.
   Google Scholar
• Borse V, Al Aameri RF, Sheehan K, et al. Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity. Cell Death Dis. 2017;8(7):e2921.
   Google Scholar
• Mukherjea D, Jajoo S, Sheehan K, et al. NOX3 NADPH oxidase couples transient receptor potential vanilloid 1 to signal transducer and activator of transcription 1-mediated inflammation and hearing loss. Antioxid Redox Signal. 2011;14(6):999–1010.
   Google Scholar
• Kaur T, Mukherjea D, Sheehan K, et al. Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation. Cell Death Dis. 2011;2:e180.
   Google Scholar
• So H, Kim H, Lee J-H, et al. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-κB. J Assoc Res Otolaryngol. 2007;8(3):338–355.
   Google Scholar
• Tsuji F, Aono H. Role of transient receptor potential vanilloid 1 in inflammation and autoimmune diseases. Pharmaceuticals (Basel). 2012;5(8):837–852.
   Google Scholar
• Bujak JK, Kosmala D, Szopa IM, et al. Inflammation, cancer and immunity-implication of TRPV1 channel. Front Oncol. 2019;9:1087.
   Google Scholar
• Mukherjea D, Jajoo S, Whitworth C, et al. Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat. J Neurosci. 2008;28(49):13056–13065.
   Google Scholar
• Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816–824.
   Google Scholar
• Bhatta P, Dhukhwa A, Sheehan K, et al. Capsaicin protects against cisplatin ototoxicity by changing the STAT3/STAT1 ratio and activating cannabinoid (CB2) receptors in the cochlea. Sci Rep. 2019;9(1):4131.
   Google Scholar
• Vlajkovic SM, Housley GD, Thorne PR. Adenosine and the auditory system. Curr Neuropharmacol. 2009;7(3):246–256.
   Google Scholar
• Ford MS, Maggirwar SB, Rybak LP, et al. Expression and function of adenosine receptors in the chinchilla cochlea. Hear Res. 1997;105(1–2):130–140.
   Google Scholar
• Kaur T, Borse V, Sheth S, et al. Adenosine A1 receptor protects against cisplatin ototoxicity by suppressing the NOX3/STAT1 inflammatory pathway in the cochlea. J Neurosci. 2016;36(14):3962–3977.
   Google Scholar
• Ghosh S, Sheth S, Sheehan K, et al. The endocannabinoid/cannabinoid receptor 2 system protects against cisplatin-induced hearing loss. Front Cell Neurosci. 2018;12:271.
   Google Scholar
• Wang W, Shanmugam MK, Xiang P, et al. Sphingosine 1-phosphate receptor 2 induces otoprotective responses to cisplatin treatment. Cancers (Basel). 2020;12(1):211–226.
   Google Scholar
• Benkafadar N, Menardo J, Bourien J, et al. Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy. EMBO Mol Med. 2017;9(1):7–26.
   Google Scholar
• Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst. 2000;92(19):1564–1572.
   Google Scholar
• Roy S, Ryals MM, Van den Bruele AB, et al. Sound preconditioning therapy inhibits ototoxic hearing loss in mice. J Clin Invest. 2013;123(11):4945–4949.
   Google Scholar
• Teitz T, Fang J, Goktug AN, et al. CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss. J Exp Med. 2018;215(4):1187–1203.
   Google Scholar
• More SS, Akil O, Ianculescu AG, et al. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci. 2010;30(28):9500–9509.
   Google Scholar
• Ciarimboli G, Deuster D, Knief A, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol. 2010;176(3):1169–1180.
   Google Scholar
• Ciarimboli G. Membrane transporters as mediators of cisplatin side-effects. Anticancer Res. 2014;34(1):547–550.
   Google Scholar
• Sheehan K, Sheth S, Mukherjea D, et al. Trans-tympanic drug delivery for the treatment of ototoxicity. J Vis Exp. 2018;133:e56564:1–7.
   Google Scholar
• Appleton TG, Connor JW, Hall JR, et al. NMR study of the reactions of the cis-diamminediaquaplatinum(II) cation with glutathione and amino acids containing a thiol group. Inorg Chem. 1989;28(11):2030–2037.
   Google Scholar
• Bijarnia RK, Bachtler M, Chandak PG, et al. Sodium thiosulfate ameliorates oxidative stress and preserves renal function in hyperoxaluric rats. PLoS One. 2015;10(4):e0124881.
   Google Scholar
• Sooriyaarachchi M, Gailer J, Dolgova NV, et al. Chemical basis for the detoxification of cisplatin-derived hydrolysis products by sodium thiosulfate. J Inorg Biochem. 2016;162:96–101.
   Google Scholar
• Sooriyaarachchi M, George GN, Pickering IJ, et al. Tuning the metabolism of the anticancer drug cisplatin with chemoprotective agents to improve its safety and efficacy. Metallomics. 2016;8(11):1170–1176.
   Google Scholar
• Duval M, Daniel SJ. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity. J Otolaryngol Head Neck Surg. 2012;41(5):309–315.
   Google Scholar
• Ekborn A, Laurell G, Johnström P, et al. D-methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics. Hear Res. 2002;165(1–2):53–61.
   Google Scholar
• Fernandez R, Harrop-Jones A, Wang X, et al. The sustained-exposure dexamethasone formulation OTO-104 offers effective protection against cisplatin-induced hearing loss. Audiol Neurootol. 2016;21(1):22–29.
   Google Scholar
• Marshak T, Steiner M, Kaminer M, et al. Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: a randomized controlled study. Otolaryngol Head Neck Surg. 2014;150(6):983–990.
   Google Scholar
• Weijl NI, Elsendoorn TJ, Lentjes EGWM, et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer. 2004;40(11):1713–1723.
   Google Scholar
• Sun C, Wang X, Chen D, et al. Dexamethasone loaded nanoparticles exert protective effects against cisplatin-induced hearing loss by systemic administration. Neurosci Lett. 2016;619:142–148.
   Google Scholar
• Paksoy M, Ayduran E, Şanlı A, et al. The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats. Med Oncol. 2011;28(2):615–621.
   Google Scholar
• Simsek G, Taş BM, Muluk NB, et al. Comparison of the protective efficacy between intratympanic dexamethasone and resveratrol treatments against cisplatin-induced ototoxicity: an experimental study. Eur Arch Otorhinolaryngol. 2019;276(12):3287–3293.
   Google Scholar
• Ozel HE, Özdoğan F, Gürgen SG, et al. Comparison of the protective effects of intratympanic dexamethasone and methylprednisolone against cisplatin-induced ototoxicity. J Laryngol Otol. 2016;130(3):225–234.
   Google Scholar
• Hill GW, Morest DK, Parham K. Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. Otol Neurotol. 2008;29(7):1005–1011.
   Google Scholar
• Parham K. Can intratympanic dexamethasone protect against cisplatin ototoxicity in mice with age-related hearing loss? Otolaryngol Head Neck Surg. 2011;145(4):635–640.
   Google Scholar
• Shafik AG, Elkabarity RH, Thabet MT, et al. Effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in adult guinea pigs. Auris Nasus Larynx. 2013;40(1):51–60.
   Google Scholar
• Murphy D, Daniel SJ. Intratympanic dexamethasone to prevent cisplatin ototoxicity: a guinea pig model. Otolaryngol Head Neck Surg. 2011;145(3):452–457.
   Google Scholar
• Waissbluth S, Salehi P, He X, et al. Systemic dexamethasone for the prevention of cisplatin-induced ototoxicity. Eur Arch Otorhinolaryngol. 2013;270(5):1597–1605.
   Google Scholar
• Dickey DT, Wu YJ, Muldoon LL, et al. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther. 2005;314(3):1052–1058.
   Google Scholar
• Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(1):63–74.
   Google Scholar
• Brock PR, Maibach R, Childs M, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med. 2018;378(25):2376–2385.
   Google Scholar
• Zuur CL, Simis YJ, Lansdaal PE, et al. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol. 2007;25(24):3759–3765.
   Google Scholar
• Rolland V, Meyer F, Guitton MJ, et al. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer. J Otolaryngol Head Neck Surg. 2019;48(1):4.
   Google Scholar
• Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014;141(2):150–159.
   Google Scholar
• Sarafraz Z, Ahmadi A, Daneshi A. Transtympanic injections of n-acetylcysteine and dexamethasone for prevention of cisplatin-induced ototoxicity: double blind randomized clinical trial. Int Tinnitus J. 2018;22(1):40–45.
   Google Scholar
• Riga MG, Chelis L, Kakolyris S, et al. Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy. Am J Clin Oncol. 2013;36(1):1–6.
   Google Scholar
• Yoo J, Hamilton SJ, Angel D, et al. Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients. Laryngoscope. 2014;124(3):E87–94.
   Google Scholar
• Visacri MB, Quintanilha JCF, Sousa VM, et al. Can acetylcysteine ameliorate cisplatin‐induced toxicities and oxidative stress without decreasing antitumor efficacy? A randomized, double‐blind, placebo‐controlled trial involving patients with head and neck cancer. Cancer Med. 2019;8(5):2020–2030.
   Google Scholar
• Church MW, Blakley BW, Burgio DL, et al. WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects. J Assoc Res Otolaryngol. 2004;5(3):227–237.
   Google Scholar
• Glover D, Ibrahim J, Kirkwood J, et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern cooperative oncology group study (E1686). Melanoma Res. 2003;13(6):619–626.
   Google Scholar
• Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a children’s oncology group study. Cancer. 2005;104(4):841–847.
   Google Scholar
• Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol. 2005;22(5):441–445.
   Google Scholar
• Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008;26(22):3749–3755.
   Google Scholar
• Kalkanis JG, Whitworth C, Rybak LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope. 2004;114(3):538–542.
   Google Scholar
• Soyalic H, Gevrek F, Koç S, et al. Intraperitoneal curcumin and vitamin E combination for the treatment of cisplatin-induced ototoxicity in rats. Int J Pediatr Otorhinolaryngol. 2016;89:173–178.
   Google Scholar
• Teranishi M, Nakashima T, Wakabayashi T. Effects of alpha-tocopherol on cisplatin-induced ototoxicity in guinea pigs. Hear Res. 2001;151(1–2):61–70.
   Google Scholar
• Fernandez K, Spielbauer KK, Rusheen A, et al. Lovastatin protects against cisplatin-induced hearing loss in mice. Hear Res. 2020;389:107905.
   Google Scholar
• Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol. 2005;16(6):624–629.
   Google Scholar
• Bu DX, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol. 2011;22(3):165–170.
   Google Scholar
• Crabb SJ, Martin K, Abab J, et al. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. Eur J Cancer. 2017;87:75–83.
   Google Scholar
• Blakley BW, Gupta AK, Myers SF, et al. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngology Head Neck Surg. 1994;120(5):541–546.
   Google Scholar
• Paken J, Govender C, Pillay M, et al. A review of cisplatin-associated ototoxicity. Semin Hear. 2019;40(2):108–121.
   Google Scholar
• Knox RJ, Friedlos F, Lydall DA, et al. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986;46(4 Pt 2):1972–1979.
   Google Scholar
• Ding D, Allman BL, Salvi R. Review: ototoxic characteristics of platinum antitumor drugs. Anat Rec (Hoboken). 2012;295(11):1851–1867.
   Google Scholar
• Hacker MP, Douple EB, Krakoff IH. Platinum coordination complexes in cancer chemotherapy. Proceedings of the fourth international symposium on platinum coordination complexes in cancer chemotherapy convened in Burlington, Vermont by the Vermont Regional Cancer Center and the Norris Cotton Cancer Center, June 22–24, 1983. Vol. 17. Burlington, Vermont: Springer Science & Business Media; 2012.
   Google Scholar
• Kidani Y, Inagaki K, Iigo M, et al. Antitumor activity of 1,2-diaminocyclohexane–platinum complexes against sarcoma-180 ascites form. J Med Chem. 1978;21(12):1315–1318.
   Google Scholar
• Grem JL, McAtee N, Balis F, et al. A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer. 1993;72(3):663–668.
   Google Scholar
• Loehrer PJ Sr., Turner S, Kubilis P, et al. A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier oncology group trial. J Clin Oncol. 1988;6(4):642–648.
   Google Scholar
• de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–2947.
   Google Scholar
• Malhotra NK, Aslam R, Lipman SP, et al. Acute ototoxicity from a single infusion of oxaliplatin. Ear Nose Throat J. 2010;89(6):258–261.
   Google Scholar
• Oh SY, Wasif N, Garcon MC, et al. Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. JOP. 2013;14(6):676–679.
   Google Scholar
• Guvenc MG, Dizdar D, Dizdar SK, et al. Sudden hearing loss due to oxaliplatin use in a patient with colon cancer. J Chemother. 2016;28(4):341–342.
   Google Scholar
• Zhang F, Wang Y, Wang ZQ, et al. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis. Dis Esophagus. 2017;30(2):1–8.
   Google Scholar
• Shimada M, Itamochi H, Kigawa J. Nedaplatin: a cisplatin derivative in cancer chemotherapy. Cancer Manag Res. 2013;5:67–76.
   Google Scholar
• Tang LQ, Chen D-P, Guo L, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(4):461–473.
   Google Scholar
• Akshintala S, Marcus L, Warren KE, et al. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. Pediatr Blood Cancer. 2015;62(4):603–610.
   Google Scholar
• Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68(4):321–331.
   Google Scholar
• Schweitzer VG, Hawkins JE, Lilly DJ, et al. Ototoxic and nephrotoxic effects of combined treatment with cis-diamminedichloroplatinumcis-diamminedichloroplatinum and kanamycin in the guinea pig. Otolaryngol Head Neck Surg. 1984;92(1):38–49.
   Google Scholar
• Riggs LC, Brummett RE, Guitjens SK, et al. Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope. 1996;106(4):401–406.
   Google Scholar
• Hallmark RJ, Snyder JM, Jusenius K, et al. Factors influencing ototoxicity in ovarian cancer patients treated with cis-platinum based chemotherapy. Eur J Gynaecol Oncol. 1992;13(1):35–44.
   Google Scholar
• Clemens E, de Vries AC, Pluijm SF, et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: a DCOG late-effects study. Eur J Cancer. 2016;69:77–85.
   Google Scholar
• Patschan D, Patschan S, Buschmann I, et al. Loop diuretics in acute kidney injury prevention, therapy, and risk stratification. Kidney Blood Press Res. 2019;44(4):457–464.
   Google Scholar
• Santoso JT, Lucci JA, Coleman RL, et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003;52(1):13–18.
   Google Scholar
• Brummett RE. Ototoxicity resulting from the combined administration of potent diuretics and other agents. Scand Audiol Suppl. 1981;14(Suppl):215–224.
   Google Scholar
• Li Y, Ding D, Jiang H, et al. Co-administration of cisplatin and furosemide causes rapid and massive loss of cochlear hair cells in mice. Neurotox Res. 2011;20(4):307–319.
   Google Scholar
• Laurell G, Engstrom B. The combined effect of cisplatin and furosemide on hearing function in guinea pigs. Hear Res. 1989;38(1–2):19–26.
   Google Scholar
• Ding D, Jiang H, Wang P, et al. Cell death after co-administration of cisplatin and ethacrynic acid. Hear Res. 2007;226(1–2):129–139.
   Google Scholar
• Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77(8):1355–1362.
   Google Scholar
• Sheth S, Sheehan K, Dhukhwa A, et al. Oral administration of caffeine exacerbates cisplatin-induced hearing loss. Sci Rep. 2019;9(1):9571.
   Google Scholar
• Sandulache VC, Chen Y, Lee J, et al. Evaluation of hyperpolarized [1-(1)(3)C]-pyruvate by magnetic resonance to detect ionizing radiation effects in real time. PLoS One. 2014;9(1):e87031.
   Google Scholar
• Schuette A, Lander DP, Kallogjeri D, et al. Predicting hearing loss after radiotherapy and cisplatin chemotherapy in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2019;146:106–112.
   Google Scholar
• Vieira WA, Weltman E, Chen MJ, et al. Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review. Radiat Oncol. 2014;9:158.
   Google Scholar
• Gratton MA, Kamen BA. Potentiation of cisplatin ototoxicity by noise. J Clin Oncol. 1990;8(12):2091–2092.
   Google Scholar
• Gratton MA, Salvi RJ, Kamen BA, et al. Interaction of cisplatin and noise on the peripheral auditory system. Hear Res. 1990;50(1–2):211–223.
   Google Scholar
• Laurell GFE. Combined effects of noise and cisplatin: short- and long-term follow-up. Ann Otol Rhinol Laryngol. 1992;101(12):969–976.
   Google Scholar
• van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer. Cochrane Database Syst Rev. 2019;5:1–73.
   Google Scholar
• Wu X, Li X, Song Y, et al. Allicin protects auditory hair cells and spiral ganglion neurons from cisplatin - induced apoptosis. Neuropharmacology. 2017;116:429–440.
   Google Scholar
• Kim K-H, Lee B, Kim Y-R, et al. Evaluating protective and therapeutic effects of alpha-lipoic acid on cisplatin-induced ototoxicity. Cell Death Dis. 2018;9(8):827.
   Google Scholar
• Rybak LP, Whitworth C, Somani S. Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope. 1999;109(11):1740–1744.
   Google Scholar
• Kalcioglu MT, Kizilay A, Gulec M, et al. The protective effect of erdosteine against ototoxicity induced by cisplatin in rats. Eur Arch Otorhinolaryngol. 2005;262(10):856–863.
   Google Scholar
• Waissbluth S, Dupuis I, Daniel SJ. Protective effect of erdosteine against cisplatin-induced ototoxicity in a guinea pig model. Otolaryngol Head Neck Surg. 2012;146(4):627–632.
   Google Scholar
• Sakat MS, Kilic K, Akdemir FNE, et al. The effectiveness of eugenol against cisplatin-induced ototoxicity. Braz J Otorhinolaryngol. 2019;85(6):766–773.
   Google Scholar
• Kim SJ, Ho Hur J, Park C, et al. Bucillamine prevents cisplatin-induced ototoxicity through induction of glutathione and antioxidant genes. Exp Mol Med. 2015;47:e142.
   Google Scholar
• Salehi P, Akinpelu OV, Waissbluth S, et al. Attenuation of cisplatin ototoxicity by otoprotective effects of nanoencapsulated curcumin and dexamethasone in a guinea pig model. Otol Neurotol. 2014;35(7):1131–1139.
   Google Scholar
• Campbell KC, Rybak LP, Meech RP, et al. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res. 1996;102(1–2):90–98.
   Google Scholar
• Li G, Sha S-H, Zotova E, et al. Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest. 2002;82(5):585–596.
   Google Scholar
• Minami SB, Sha SH, Schacht J. Antioxidant protection in a new animal model of cisplatin-induced ototoxicity. Hear Res. 2004;198(1–2):137–143.
   Google Scholar
• Lee JS, Kang SU, Hwang HS, et al. Epicatechin protects the auditory organ by attenuating cisplatin-induced ototoxicity through inhibition of ERK. Toxicol Lett. 2010;199(3):308–316.
   Google Scholar
• Korver KD, Rybak LP, Whitworth C, et al. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg. 2002;126(6):683–689.
   Google Scholar
• Wimmer C, Mees K, Stumpf P, et al. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol. 2004;25(1):33–40.
   Google Scholar
• Celebi S, Gurdal MM, Ozkul MH, et al. The effect of intratympanic vitamin C administration on cisplatin-induced ototoxicity. Eur Arch Otorhinolaryngol. 2013;270(4):1293–1297.
   Google Scholar
• Shin YS, Song SJ, Kang SU, et al. A novel synthetic compound, 3-amino-3-(4-fluoro-phenyl)-1H-quinoline-2,4-dione, inhibits cisplatin-induced hearing loss by the suppression of reactive oxygen species: in vitro and in vivo study. Neuroscience. 2013;232:1–12.
   Google Scholar
• Li G, Frenz DA, Brahmblatt S, et al. Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology. 2001;22(2):163–176.
   Google Scholar
• Choe WT, Chinosornvatana N, Chang KW. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol. 2004;25(6):910–915.
   Google Scholar
• Ramaswamy B, Roy S, Apolo AB, et al. Magnetic nanoparticle mediated steroid delivery mitigates cisplatin induced hearing loss. Front Cell Neurosci. 2017;11:268.
   Google Scholar
• Demir MG, Altintoprak N, Aydin S, et al. Effect of transtympanic injection of melatonin on cisplatin-induced ototoxicity. J Int Adv Otol. 2015;11(3):202–206.
   Google Scholar
• Wang J, Lloyd Faulconbridge RV, Fetoni A, et al. Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. Neuropharmacology. 2003;45(3):380–393.
   Google Scholar
• Martin-Saldana S, Palao-Suay R, Aguilar MR, et al. Polymeric nanoparticles loaded with dexamethasone or alpha-tocopheryl succinate to prevent cisplatin-induced ototoxicity. Acta Biomater. 2017;53:199–210.
   Google Scholar
• Martin-Saldana S, Palao-Suay R, Aguilar MR, et al. pH-sensitive polymeric nanoparticles with antioxidant and anti-inflammatory properties against cisplatin-induced hearing loss. J Control Release. 2018;270:53–64.
   Google Scholar
• Yuksel Aslier NG, Tağaç AA, Durankaya SM, et al. Dexamethasone-loaded chitosan-based genipin-cross-linked hydrogel for prevention of cisplatin induced ototoxicity in Guinea pig model. Int J Pediatr Otorhinolaryngol. 2019;122:60–69.
   Google Scholar
• Wang X, Chen Y, Tao Y, et al. A666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss. Int J Nanomedicine. 2018;13:7517–7531.
   Google Scholar
• Berglin CE, Pierre PV, Bramer T, et al. Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model. Cancer Chemother Pharmacol. 2011;68(6):1547–1556.
   Google Scholar
• Teranishi MA, Nakashima T. Effects of trolox, locally applied on round windows, on cisplatin-induced ototoxicity in guinea pigs. Int J Pediatr Otorhinolaryngol. 2003;67(2):133–139.
   Google Scholar
• Spankovich C, Lobarinas E, Ding D, et al. Assessment of thermal treatment via irrigation of external ear to reduce cisplatin-induced hearing loss. Hear Res. 2016;332:55–60.
   Google Scholar
• Villani V, Zucchella C, Cristalli G, et al. Vitamin E neuroprotection against cisplatin ototoxicity: preliminary results from a randomized, placebo-controlled trial. Head Neck. 2016;38(Suppl 1):E2118–21.
   Google Scholar